Contribution of Human Immunodeficiency Virus Type 1 Minority Variants to Reduced Drug Susceptibility in Patients on an Integrase Strand Transfer Inhibitor-Based Therapy

Sensitive Deep-Sequencing-Based HIV-1 Genotyping Assay To Simultaneously Determine Susceptibility to Protease, Reverse Transcriptase, Integrase, and Maturation Inhibitors, as Well as HIV-1 Coreceptor Tropism

(2014) Richard M. Gibson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Prevalence and Evolution of Low Frequency HIV Drug Resistance Mutations Detected by Ultra Deep Sequencing in Patients Experiencing First Line Antiretroviral Therapy Failure

(2014) Marie-Anne Vandenhende et al.   PLoS One

Molecular basis of human immunodeficiency virus type 1 drug resistance: Overview and recent developments

(2013) Luis Menéndez-Arias   ANTIVIRAL RESEARCH

Clinical Implications of HIV-1 Minority Variants

(2013) Jonathan Z. Li et al.   CLINICAL INFECTIOUS DISEASES

Emerging strategies to deplete the HIV reservoir

(2013) Nancie M. Archin et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Sensitive Cell-Based Assay for Determination of Human Immunodeficiency Virus Type 1 Coreceptor Tropism

(2013) J. Weber et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Evaluation of a Benchtop HIV Ultradeep Pyrosequencing Drug Resistance Assay in the Clinical Laboratory

(2013) Boaz Avidor et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Rapid deep sequencing of patient-derived HIV with ion semiconductor technology

(2013) Max W. Chang et al.   JOURNAL OF VIROLOGICAL METHODS

WHO's new guidelines for antiretroviral treatment

(2013) Patricia E Fast et al.   LANCET

Resistance Mutations outside the Integrase Coding Region Have an Effect on Human Immunodeficiency Virus Replicative Fitness but Do Not Affect Its Susceptibility to Integrase Strand Transfer Inhibitors

(2013) Jan Weber et al.   PLoS One

Impact of Minority Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Resistance Genotype After Virologic Failure

(2012) Jonathan Z. Li, Roger Paredes, Heather J. Ribaudo, Michael J. Kozal, Evguenia S. Svarovskaia, Jeffrey A. Johnson, Anna Maria Geretti, Karin J. Metzner et al.   JOURNAL OF INFECTIOUS DISEASES

Deep Sequencing Reveals Minor Protease Resistance Mutations in Patients Failing a Protease Inhibitor Regimen

(2012) R. Fisher et al.   JOURNAL OF VIROLOGY

Virologic Failures on Initial Boosted-PI Regimen Infrequently Possess Low-Level Variants with Major PI Resistance Mutations by Ultra-Deep Sequencing

(2012) Max Lataillade et al.   PLoS One

Low-Cost Ultra-Wide Genotyping Using Roche/454 Pyrosequencing for Surveillance of HIV Drug Resistance

(2012) Dawn M. Dudley et al.   PLoS One

K65R in Subtype C HIV-1 Isolates from Patients Failing on a First-Line Regimen Including d4T or AZT: Comparison of Sanger and UDP Sequencing Data

(2012) Patricia Recordon-Pinson et al.   PLoS One

Prolonged and Substantial Discordance in Prevalence of Raltegravir-Resistant HIV-1 in Plasma versus PBMC Samples Revealed by 454 “Deep” Sequencing

(2012) Guinevere Q. Lee et al.   PLoS One

Ultra-Deep Sequencing of HIV-1 Reverse Transcriptase Before Start of an NNRTI-based Regimen in Treatment-naive Patients

(2012) Peter Messiaen et al.   VIROLOGY

Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment-naïve HIV-1-infected patients

(2012) A Zolopa et al.   Journal of the International AIDS Society

HIV cure and eradication: how will we get from the laboratory to effective clinical trials?

(2011) Sharon R Lewin et al.   AIDS

Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure

(2011) Jonathan Z. Li et al.   AIDS

Novel Method for Simultaneous Quantification of Phenotypic Resistance to Maturation, Protease, Reverse Transcriptase, and Integrase HIV Inhibitors Based on 3′Gag(p2/p7/p1/p6)/PR/RT/INT-Recombinant Viruses: a Useful Tool in the Multitarget Era of Antiretroviral Therapy

(2011) Jan Weber et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Deep V3 Sequencing for HIV Type 1 Tropism in Treatment-Naive Patients: A Reanalysis of the MERIT Trial of Maraviroc

(2011) Luke C. Swenson et al.   CLINICAL INFECTIOUS DISEASES

Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure

(2011) Jonathan Z. Li   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications

(2011) Jose-Luis Blanco et al.   JOURNAL OF INFECTIOUS DISEASES

HIV-1 nucleotide mixture detection in the virco®TYPE HIV-1 genotyping assay: A comparison between Sanger sequencing and 454 pyrosequencing

(2011) Hans De Wolf et al.   JOURNAL OF VIROLOGICAL METHODS

MEGA5: Molecular Evolutionary Genetics Analysis Using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods

(2011) K. Tamura et al.   MOLECULAR BIOLOGY AND EVOLUTION

Added Value of Deep Sequencing Relative to Population Sequencing in Heavily Pre-Treated HIV-1-Infected Subjects

(2011) Francisco M. Codoñer et al.   PLoS One

Prevalence and Impact of Minority Variant Drug Resistance Mutations in Primary HIV-1 Infection

(2011) Joanne D. Stekler et al.   PLoS One

Detection of Inferred CCR5- and CXCR4-Using HIV-1 Variants and Evolutionary Intermediates Using Ultra-Deep Pyrosequencing

(2011) Evelien M. Bunnik et al.   PLoS Pathogens

Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy

(2010) Derrick D Goodman et al.   AIDS

Tenofovir (TDF)-Selected or Abacavir (ABC)-Selected Low-Frequency HIV Type 1 Subpopulations During Failure with Persistent Viremia as Detected by Ultradeep Pyrosequencing

(2010) Richard T. D'Aquila et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor

(2010) Masanori Kobayashi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Deep Sequencing to Infer HIV-1 Co-Receptor Usage: Application to Three Clinical Trials of Maraviroc in Treatment-Experienced Patients

(2010) L. C. Swenson et al.   JOURNAL OF INFECTIOUS DISEASES

Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical Trial

(2010) Andrew R. Zolopa et al.   JOURNAL OF INFECTIOUS DISEASES

Minority Variants of Drug‐Resistant HIV

(2010) Sara Gianella et al.   JOURNAL OF INFECTIOUS DISEASES

HIV Drug Resistance Surveillance Using Pooled Pyrosequencing

(2010) Hezhao Ji et al.   PLoS One

The evolution of HIV treatment guidelines: Current state-of-the-art of ART

(2009) Andrew R. Zolopa   ANTIVIRAL RESEARCH

Clinical management of HIV-1 resistance

(2009) Roger Paredes et al.   ANTIVIRAL RESEARCH

Strand transfer inhibitors of HIV-1 integrase: Bringing IN a new era of antiretroviral therapy

(2009) Damian J. McColl et al.   ANTIVIRAL RESEARCH

A novel yeast-based recombination method to clone and propagate diverse HIV-1 isolates

(2009) Dawn M. Dudley et al.   BIOTECHNIQUES

Low-Abundance Drug-Resistant Viral Variants in Chronically HIV-Infected, Antiretroviral Treatment–Naive Patients Significantly Impact Treatment Outcomes

(2009) Birgitte B. Simen et al.   JOURNAL OF INFECTIOUS DISEASES

Low-Abundance HIV Drug-Resistant Viral Variants in Treatment-Experienced Persons Correlate with Historical Antiretroviral Use

(2009) Thuy Le et al.   PLoS One

Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection

(2008) Vincenzo Summa et al.   JOURNAL OF MEDICINAL CHEMISTRY

Minority Human Immunodeficiency Virus Type 1 Variants in Antiretroviral-Naive Persons with Reverse Transcriptase Codon 215 Revertant Mutations

(2008) Y. Mitsuya et al.   JOURNAL OF VIROLOGY